I Spent a Week Chasing the “Real” SS-31 Dose. I Found a Number Borrowed From a Trial That Flunked.
Here’s the question that started this: what’s the actual dose of SS-31? Not “a” dose, the dose, the one backed by something more solid than a Discord thread. I figured this would take an afternoon. It took a week, three PDFs of a Neurology paper, and one very unglamorous afternoon on the FDA’s Drugs@FDA portal. What I came out with wasn’t a dose. It was a timeline, and once I laid the dates out side by side, the whole “40 mg” thing started to look less like science and more like a number that got frozen in place while the actual evidence kept moving underneath it.
I want to say up front: I’m not a clinician, I don’t play one on the internet, and nothing here is a recommendation for what to inject into your own body. I’m just going to show you what I found and where I found it, so you can go check it yourself.
What I dug up first: the number everyone quotes
Type “SS-31 dose” into anything and you’ll land, over and over, on 40 mg a day, subcutaneous. It’s presented with the confidence of a dosage printed on an aspirin bottle. So I went looking for its birth certificate.
It’s MMPOWER-3. This is the phase 3 trial of elamipretide, published in Neurology in 2023, and it dosed people at exactly 40 mg per day, subcutaneous, for 24 weeks [P1]. That’s the origin of the number, full stop. That part checks out.
Here’s what stopped me cold. MMPOWER-3 randomized 218 adults with primary mitochondrial myopathy, and at that 40 mg dose, it did not beat placebo. Not on the six-minute walk test, not on total fatigue, the two things the trial was built to measure. It missed both its primary and secondary endpoints [P1]. So the most commonly quoted “SS-31 dose” online is, specifically, the dose that was tested rigorously and came up empty. Nobody selling this number mentions that part. I had to go pull the trial to learn it.
What surprised me: there’s a second number, and it’s tangled up worse
Digging further, I found a second dose floating around, usually deployed by whoever wants a more optimistic story. It comes from MMPOWER, the earlier phase 1/2 trial, published in Neurology in 2018. At its highest dose, people walked farther on the six-minute walk test after five days, and the study’s own language was that elamipretide “increased exercise performance after 5 days of treatment in patients with PMM without increased safety concerns” [P2].
Fine, that’s a real result, and I’m not going to pretend it isn’t. But I kept staring at two details that never make it into the dosing charts. First: that trial dosed people intravenously, in a clinical setting, not with a subcutaneous needle at the kitchen table [P2]. Second: it was a five-day signal, and the bigger, longer trial that came after it, the one I just described, failed to confirm it [P1]. So the “good” number comes from a different route of delivery, in a controlled setting, measuring something short-term that didn’t hold up when tested properly. Take an IV result from a hospital and hand someone a home subcutaneous protocol built on it, and you’ve quietly swapped the study out from under the claim.
That route switch is the thing that actually surprised me most in this whole dig, more than the failed endpoint. Drug companies don’t casually change how they deliver a compound between trials. They do it because route of administration changes how much drug gets into the bloodstream, how fast, and how high it peaks. That’s not a footnote, that’s the whole reason MMPOWER and MMPOWER-3 are two separate studies. And yet the protocols circulating online cite the optimistic IV result and then hand you a subcutaneous recipe, as if the seam isn’t there. Once I saw it, I couldn’t stop seeing it in every “SS-31 protocol” post I opened.
What I found when I went looking for a real, legal dose
So is there anywhere SS-31 actually has an official number attached? Yes, exactly one place, and it has nothing to do with why most people are buying it. In September 2025, the FDA approved elamipretide under the brand name Forzinity, for improving muscle strength in patients with Barth syndrome who weigh at least 30 kg [P3]. That’s a real, specific, labeled dose, and you can verify it yourself in the FDA’s own record [P3].
But here’s why that doesn’t rescue anyone reading a dosing chart for energy or recovery: Barth syndrome is an ultra-rare genetic condition, and the approved dosing belongs to a specific product, for that disease, in that population. A label dose isn’t a floating number you can transplant onto a different goal. It’s tied to the drug, the disease, and the patients it was actually studied in. Even the one legitimate, FDA-blessed dose on the books is the wrong tool for what most people searching “SS-31 dose” actually want.
What I’d conclude, laying all three dates side by side
When I lined this up chronologically, it read almost like a chain of custody, and honestly that’s what convinced me the popular number is worthless for its intended use:
2018: MMPOWER shows a short-term walking improvement, via IV, in a clinical setting [P2]. 2023: MMPOWER-3 takes that hope into a bigger, longer trial, switches to subcutaneous dosing at 40 mg/day, and misses both endpoints [P1]. 2025: The FDA approves elamipretide, but only for Barth syndrome, an entirely different population, with its own labeled dose [P3].
Somewhere in that seven-year stretch, the internet grabbed the middle data point, the failed 40 mg trial, stripped off the “it failed” part, and started repeating it as a settled fact. The evidence kept evolving. The quoted number didn’t move at all. That mismatch, a static marketing number sitting on top of a moving, mostly disappointing evidence base, is the real story here, more than any single trial result.
And underneath all three of those dates sits the mechanism, which is genuinely well established even if the dosing isn’t: SS-31 binds to cardiolipin, a lipid on the inner mitochondrial membrane, and appears to help protect its structure [P4]. That’s real biochemistry. It is not, on its own, a dose for anything.
The part that actually worried me more than the dose question
Somewhere in the middle of this dig I realized I’d been asking the wrong question. Everyone, myself included, starts with “what’s the right dose.” But the dose is the second problem. The first problem is that a lot of the SS-31 sold as a “research chemical” has never been checked by anyone for what’s actually in the vial, its identity, its strength, or its purity. So even in the fantasy world where a correct dose existed for energy or recovery, you’d have no reliable way to hit it, because you don’t actually know the concentration of what you’re measuring. It’s like arguing over which decimal place to round to on a scale you don’t trust.
What I’d do if I were considering this at all
If someone in my life told me they wanted to try SS-31, my honest advice, after a week with these papers, is that the dose question shouldn’t come first. The oversight question should. Going through a licensed clinician means a real evaluation of your history, actual screening, and a preparation that comes out of a regulated compounding pharmacy, rather than guessed measurements out of a mystery powder.
FormBlends is one example of what that supervised path looks like in practice: physician evaluation, a prescription only when it’s appropriate, and dispensing through a licensed compounding pharmacy, not a vial dropped in the mail with no questions asked. They also offer a tracker app, which is just a logging tool for dose and symptoms between visits, not a prescription and not a shopping cart. None of that manufactures a proven dose that doesn’t exist. What it does is turn blind self-experimentation into something documented that a clinician can actually look at and respond to, which given how thin this evidence is, seems like the only honest upgrade on offer.
Where I landed
I went looking for the correct SS-31 dose. What I found was a number lifted from a trial that failed [P1], a more encouraging number from a different delivery route and a short-term result that didn’t survive a real test [P2], and exactly one legitimate approved dose that belongs to an ultra-rare disease, not to anyone chasing energy or recovery [P3]. Layer on top of that the fact that most of what’s sold as SS-31 hasn’t been verified for what it even contains, and “what’s the right dose” stops being a useful question at all.
If you take one thing from my week with these PDFs, let it be this: when a dosing chart looks perfectly precise, go find out what it’s quietly quoting. In this case, the receipt says “failed trial.” I’d want to know that before I trusted the number.
Answers to the common questions
Where does the 40 mg SS-31 dose everyone quotes actually come from? It’s lifted from MMPOWER-3, the phase 3 elamipretide trial published in Neurology in 2023, which dosed participants at 40 mg per day subcutaneously for 24 weeks [P1]. The part that gets left out is that this exact dose failed to beat placebo in that trial. The most-repeated SS-31 number is the dose that was tested and didn’t work, not the dose that did.
Is there any clinically proven SS-31 dose for energy, fatigue, recovery, or anti-aging? No, and I looked. There’s no established human dose for any of those uses, because there’s no human trial showing they work at any dose [P1]. The underlying mechanism is documented, SS-31 binds cardiolipin on the inner mitochondrial membrane and appears to help protect its structure [P4], but a mechanism is not a dose, and those wellness uses were never actually trialed.
Why can’t I just borrow the dose from the earlier trial that showed a benefit? Because that result came from intravenous dosing in a controlled clinical setting, not the subcutaneous home injection most protocols describe, and it was a short-term, five-day signal that the bigger MMPOWER-3 trial later failed to confirm [P2][P1]. Route of administration changes how much drug reaches your bloodstream and how fast, which is exactly why the researchers ran it as two separate trials instead of assuming the dose would transfer.
Does the FDA approval of elamipretide give me a usable dose? Not for the reason most people are buying it. In September 2025, the FDA approved elamipretide as Forzinity, specifically for improving muscle strength in patients with Barth syndrome who weigh at least 30 kg, with labeled dosing tied to that disease and that product [P3]. A label dose belongs to the drug, the disease, and the population it was studied in. It doesn’t transfer to a research-chemical vial or an energy-and-recovery goal.
Even if a correct dose existed, could I actually hit it with a research-chemical vial? Probably not reliably, which is something I didn’t fully appreciate until I dug into it. A research-chemical SS-31 sold “for research use only” hasn’t been checked by anyone for identity, strength, or purity, so you can’t be confident about the true concentration of what you’re measuring out. Precision dosing on top of an unverified product is a bit of a magic trick.
If I still wanted to try SS-31, what’s the safer route? Going through a licensed clinician, so a real person reviews your history, screens you, and dispenses a known-quality preparation through a regulated compounding pharmacy, instead of you guessing at a dose from a mystery vial. FormBlends is one example of that model: physician evaluation, a prescription when it’s appropriate, a licensed compounding pharmacy, and a tracker app for logging dose and symptoms between visits. That setup doesn’t invent a proven dose out of nowhere, but it does swap blind self-experiment for something documented and supervised.
Sources
- Pivotal phase 3 trial (MMPOWER-3): 218 adults with primary mitochondrial myopathy randomized to 40 mg/day subcutaneous elamipretide or placebo for 24 weeks; no significant difference from placebo on the six-minute walk test or total fatigue, and the trial did not meet its primary or secondary endpoints. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Karaa A, et al. Neurology, 2023. https://pubmed.ncbi.nlm.nih.gov/37268435/ (full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC10382259/)
- Earlier phase 1/2 dose-escalation trial (MMPOWER): short-term intravenous elamipretide improved six-minute walk distance at the highest dose after 5 days (adjusted difference statistically significant); “elamipretide increased exercise performance after 5 days of treatment in patients with PMM without increased safety concerns.” Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Karaa A, et al. Neurology, 2018.
- FDA approval record for elamipretide (Forzinity), NDA 215244: accelerated approval to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg, with its own labeled dosing for that indication and population. U.S. Food and Drug Administration, Drugs@FDA.
- SS-31 binds with high affinity to cardiolipin on the inner mitochondrial membrane, helping protect cristae structure (mechanism study; a mechanism, not a dose). The mitochondria-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Birk AV, et al. (Szeto HH senior author). Journal of the American Society of Nephrology, 2013.
SS-31, also known as elamipretide, remains investigational for the uses most searches are chasing. It’s FDA-approved, as Forzinity, only for Barth syndrome under accelerated approval, and its largest trial in primary mitochondrial myopathy did not beat placebo at the dose it tested. Talk to a licensed clinician before making any decision about it.
What is SS-31 peptide and how does it work?
SS-31 is a synthetic tetrapeptide, also called elamipretide, built to bind to cardiolipin, a lipid found almost exclusively in the inner mitochondrial membrane. By anchoring there, it’s thought to stabilize membrane structure and cut down oxidative stress at its source. Most of what we know comes from animal studies plus a handful of small human trials, so I’d call the picture still unfinished.
Does SS-31 peptide actually work in humans?
The honest answer, after reading the trials myself, is that the early evidence is interesting but not conclusive. Animal data showed real mitochondrial benefits, which is what pushed researchers into human trials. Those human trials, including a large heart failure study, largely did not hit their primary endpoints. Some researchers think dosing and delivery were the sticking point. Others think the biology just doesn’t map as cleanly from animals to people as hoped. Right now, no regulatory agency has approved it for any of the uses it’s popularly sold for.
Is SS-31 peptide legal to buy and use?
It sits in a regulatory gray zone in most places. It’s not an approved consumer product, so selling it for human use outside of a prescription generally isn’t permitted. In the U.S., it can legally be compounded for a specific patient under a physician’s supervision, which is the route some clinics take. Buying it from research-chemical sites that label it “not for human use” to dodge regulation carries real legal and safety uncertainty, and that’s before you even get to the dosing questions above.
What are the known side effects of SS-31 peptide?
In the published clinical trials, SS-31 was generally well tolerated at the doses tested, with injection-site reactions being the most commonly reported issue. Systemic side effects weren’t dramatically different from placebo in most reports I found. But these trials were short and enrolled carefully chosen patients, so long-term safety data in otherwise healthy people using it for longevity or performance simply doesn’t exist yet. Physician oversight, through something like a compounding pharmacy such as FormBlends, at least means someone is watching for problems as they come up.
